Romiplostim for management of refractory immune thrombocytopenic purpura in the immediate postpartum period. Issue 5 (18th May 2020)

• Record Type: Journal Article
• Authors: Patras, Ariana; Figueroa, Reinaldo; Singh, Amit P; Madan, Ichchha
• Is Part Of: BMJ case reports. Volume 13:Issue 5(2020)
• Publication Date: 2020-05-18
• Subjects: obstetrics, gynaecology and fertility -- haematology (incl blood transfusion) -- pregnancy; Medicine -- Case studies -- Periodicals; 610.5
• DOI: 10.1136/bcr-2020-234335
• Languages: English
• ISSNs: 1757-790X

Abstract

Abstract : We present a case of a pregnant woman with chronic immune thrombocytopenic purpura and chronic hypertension who developed pre-eclampsia with severe features warranting delivery. Her overall clinical picture and liver enzymes improved in the immediate postpartum period, however, aggressively progressing thrombocytopenia posed a diagnostic dilemma to the interdisciplinary care team. After failing to respond to first-line therapies including high-dose corticosteroids and intravenous immunoglobulin, she was successfully managed with a trial of the thrombopoietin receptor agonist, Romiplostim.